SIRT5 is also significantly expressed in prostate cancer, where it activates acetyl-CoA acetyltransferase 1 (ACAT1) and induces a mitogen-activated protein kinase (MAPK) pathway. Here, ACAT1 is linked to prostate carcinoma.